Life Sciences Partners backs Activaero

Existing investors BioMedPartners AG, VI Partners AG, Abalis Finance AG, Vesalius Biocapital I SICAR S.A., MedVenture Partners and existing shareholders contributed a further €1.5 in this round. The capital will be used to complete clinical development of its asthma programme and continue clinical developments using its controlled breathing inhalation devices.

Activaero is a developer of controlled breathing drug delivery technologies. The business is headquartered in Gemünden, Germany and also operates in Munich and Dublin, Ohio.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• DACH
• Early-stage
• Healthcare